Hospitals and clinics that specialize in the treatment of urea cycle disorders (UCD) and protein toxicity are primarily members of the Urea Cycle Disorders Consortium (UCDC), an international network of metabolic centers. These centers employ multidisciplinary teams, including metabolic geneticists, metabolic dietitians, and genetic counselors, to manage the complex needs of patients. [1, 2, 3, 4]
Leading Hospitals and Clinics
The following institutions are recognized as key research and treatment centers for UCD. Many are pediatric hospitals but often provide transitional care or have adult metabolic programs. [3, 5]
| Hospital / Clinic [2, 5, 6, 7, 8, 9, 10, 11] | Location | Specialty Focus |
|---|---|---|
| Children’s National Medical Center | Washington, D.C. | Lead UCDC site; world leader in UCD research |
| Children’s Hospital of Philadelphia (CHOP) | Philadelphia, PA | Pioneer in cell and gene therapy for UCD |
| Baylor College of Medicine / Texas Children’s | Houston, TX | Advanced DNA sequencing and biomarker research |
| Ann & Robert H. Lurie Children’s Hospital | Chicago, IL | Longitudinal studies on physical and neurological impact |
| Boston Children’s Hospital / Harvard | Boston, MA | Research on silent seizures in hyperammonemia |
| Lucile Packard Children’s Hospital Stanford | Palo Alto, CA | Clinical research and innovative treatments |
| UPMC Children’s Hospital of Pittsburgh | Pittsburgh, PA | Dedicated Center for Rare Disease Therapy |
| Hospital for Sick Children (SickKids) | Toronto, Canada | International UCDC research partner |
Leading Doctors and Specialists
The experts listed below are principal investigators within the UCDC and are renowned for their work in metabolic genetics and pediatric care. [2, 12]
- Dr. Mark Batshaw (Children’s National): Global leader in UCD research and nationwide clinical programs.
- Dr. Mendel Tuchman (Children’s National): Elite provider specializing in N-Acetylglutamate Synthase Deficiency and pediatric genetics.
- Dr. Brendan Lee (Baylor College of Medicine): Expert in metabolic genetics and neurodevelopmental outcomes.
- Dr. Marc Yudkoff (Children’s Hospital of Philadelphia): Specializes in pediatric metabolic disease and UCD research.
- Dr. Jerry Vockley (UPMC Children’s): Chief of Genetic and Genomic Medicine and a global leader in inborn errors of metabolism.
- Dr. Nicholas Ah-Mew (Children’s National): Pediatric specialist focusing on comparing UCD treatment options.
- Dr. Sandesh Nagamani (Baylor College of Medicine): Research focused on clinical trials and long-term management of UCD. [2, 6, 7, 12, 13, 14, 15, 16, 17]
Specialist Types and Age Groups
- Medical Genetics / Metabolic Specialists: These are the primary doctors for UCD. They typically treat pediatric patients from birth, but many work in academic centers that also manage adults with milder or late-onset forms of the disorder.
- Metabolic Dietitians: Critical for managing the strict low-protein diet required to prevent protein toxicity (hyperammonemia) across all age groups.
- Primary Care / Family Medicine: Some family physicians (e.g., Dr. John Gleason) are rated as experienced in UCD for providing ongoing care for individuals of all ages. [1, 2, 3, 4, 18]
In 2003, the National Institutes of Health (NIH) developed the pioneering Rare Diseases Clinical Research Network (RDCRN) in order to promote and fund collaborative research on rare diseases. To answer this call, the Urea Cycle Disorders Consortium (UCDC), comprised of 5 academic centers, and led by Dr. Mark L. Batshaw of Children’s National Medical Center, was founded with the collaboration of the National Urea Cycle Disorders Foundation. The UCDC was awarded its first 5-year grant by NIH-RDCRN to study urea cycle disorders. Only 11 rare disease consortiums received this prestigious award. Five years later, in 2008, the RDCRN offered another round of funding to rare diseases researchers through a highly competitive grant process. The UCDC applied, received the highest score of all applications, and was awarded another 5-year grant to continue UCD research. In 2014, UCDC received its fourth consecutive award, attaining a perfect score of 10 on the grant review, and in 2019, the UCDC received a fifth consecutive funding award. Additional funding is being provided by matching grants from private family foundations. The National Urea Cycle Disorders Foundation provides funding for neuroimaging studies at the Georgetown University site, and funds 2 additional research centers at Stanford University Lucile Packard Children’s Hospital and the University of California San Francisco.
The purpose of the UCDC is to perform cutting-edge research to improve the understanding of UCD and to accelerate new treatments. The UCDC includes teams of doctors, nurses, research coordinators and research laboratories at 14 academic centers in the US, Canada and Europe working together and in close collaboration with the National Urea Cycle Disorders Foundation. One of the key roles the Foundation plays is ensuring the needs and wishes of UCD patients and families are met as we strive to improve their lives and learn more about preventing the effects of urea cycle disorders.
“The collaboration has provided a unique environment which has led to discoveries that have improved outcome for affected patients that we could have only dreamed about before the Rare Disease Clinical Research Network came into being,” says Dr. Batshaw. Rare diseases affect over 25 million Americans, but only a handful have any treatments available. Since 2003, the UCDC and NUCDF have assisted in the development and FDA approval of three new drugs to treat urea cycle disorders by bringing together stakeholders, developing clinical trial protocols, and conducting clinical trials at the UCDC sites. The UCDC collaboration now extends internationally to include the inborn error of metabolism researcher groups in Japan, Australia, and Europe.
Many patients and families with urea cycle disorders struggle to obtain an accurate diagnosis and access life-saving treatment. The UCDC sites are “centers of excellence” for diagnosis, treatment and monitoring, and have improved both identification and outcomes for patients.
Dr. Tuchman stated that “the creation and funding of the UCDC has been the culmination of many years of clinical and research work…patients with UCD now have new hopes for a better future as a result of the projects conducted by the UCDC.” The UCDC has helped develop newborn screening technology to improve diagnosis, and conducts research on brain function using advanced neuroimaging techniques at the Georgetown site (Dr. Andrea Gropman). These neuroimaging techniques are unlocking the mysteries of the effects of UCD on brain function and are the foundation for developing new treatments to prevent these devastating effects.
The UCDC also trains the next generation of clinicians and researchers, and provides education on UCDs to healthcare professionals and the public through its partnership with the National Urea Cycle Disorders Foundation.
[1] https://www.ravictihcp.com
[3] https://pmc.ncbi.nlm.nih.gov
[4] https://www.ucdincommon.com
[5] https://ucdc.rarediseasesnetwork.org
[6] https://research.childrensnational.org
[7] https://research.childrensnational.org
[10] https://nucdf.org
[11] https://www.chp.edu
[13] https://nucdf.org
[14] https://pmc.ncbi.nlm.nih.gov
[15] https://nucdf.org
[16] https://www.chp.edu
[17] https://www.ncbi.nlm.nih.gov
Specialized care for protein toxicity, particularly Urea Cycle Disorders (UCDs), is primarily managed by biochemical geneticists and metabolic specialists at dedicated metabolic centers. The leading authority in the United States is the Urea Cycle Disorders Consortium (UCDC), a network of research and clinical centers. [1, 2, 3, 4, 5]